Somatostatin receptor imaging in somatotroph and non‐functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

Borson‐Chazot, Françoise; Houzard, C.; Ajzenberg, C.; Nocaudie, M.; Duet, M.; Mundler, O.; Marchandise, X.; Epelbaum, Jacques; Alzaga, Maria Gomez De; Schäfer, Judith; Meyerhof, Wolfgang; Sassolas, G.; Warnet, A

doi:10.1046/j.1365-2265.1997.3361119.x

Cited by 56 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it can be expected that most GH-secreting tumors can be visualized using 111 In-pentetreotide. Several studies in patients with acromegaly have shown a close association between the increased 111 In-pentetreotide uptake in the pituitary tumor and the inhibition of the pathologic GH secretion by octapeptide somatostatin analogs [15][16][17][18][19][20][21][22]. However, other studies could not reproduce these findings [23][24][25][26].…”

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

“…Various studies have demonstrated positive effects of this therapy on tumor size, visual field disturbances, or excessive secretion of tumor products in patients harboring these tumors [41][42][43]. Like in acromegaly, some studies in clinically non-functioning pituitary adenomas have shown a positive correlation between pituitary uptake of 111 In-pentetreotide and the inhibition of tumor growth, or excessive hormonal secretion (like FSH, LH or glycoprotein hormone subunits in some patients), or the improvement in visual field defects by octapeptide somatostatin analog therapy [15,22,41,44]. Generally, negative 111 In-pentetreotide scintigraphy predicted failure of somatostatin analogs to produce any kind of response in these studies [15].…”

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

“…Like in acromegaly, some studies in clinically non-functioning pituitary adenomas have shown a positive correlation between pituitary uptake of 111 In-pentetreotide and the inhibition of tumor growth, or excessive hormonal secretion (like FSH, LH or glycoprotein hormone subunits in some patients), or the improvement in visual field defects by octapeptide somatostatin analog therapy [15,22,41,44]. Generally, negative 111 In-pentetreotide scintigraphy predicted failure of somatostatin analogs to produce any kind of response in these studies [15]. However, other studies could also not show any positive correlation between 111 In-pentetreotide scintigraphypositivity and clinical or biochemical response in these tumors [23,24].…”

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

See 2 more Smart Citations

Somatostatin Analogs as Radiodiagnostic Tools

Herder

Lamberts

2005

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin Analogs as Radiodiagnostic Tools

Herder

Lamberts

2005

Rev Endocr Metab Disord

View full text Add to dashboard Cite

“…A cintilografia com 111In-Pentreotide tem boa correlação com a resposta ao tratamento com octreotide (27,31,32), no entanto o seu alto custo limita o seu uso rotineiro.…”

Section: Teste Agudo Com Octreotide Subcutâneounclassified

Teste agudo com octreotide subcutâneo como preditor de resposta ao tratamento com octreotide LAR®

Taboada

Donangelo

Guimarães

et al. 2005

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOOs análogos da somatostatina são muito utilizados no tratamento da acromegalia. Com o objetivo de determinar o valor do teste agudo (TA) com octreotide subcutâneo (SC) como preditor da resposta ao tratamento com octreotide LAR ® , analisamos os dados de 20 pacientes. Para o TA, amostras de sangue foram colhidas antes e duas horas após a administração de octreotide SC para a dosagem de GH. Os níveis de GH antes e após o TA foram 21,9 (2,3-143,4) e 3,1ng/mL (0,3-61,3), respectivamente. Foi considerado controle de doença: GH< 2,5ng/mL e IGF-I normal em algum momento durante o tratamento. A sensibilidade, especificidade e os valores preditivos positivo e negativo do TA foram 0,9, 0,6, 0,69 e 0,86 para redução de 75% do GH no teste. Concluímos que, em nossa casuística, um decréscimo de 75% dos níveis de GH no TA teve um bom poder discriminatório entre pacientes com maior e menor chance de resposta ao tratamento. ABSTRACT Acute Test With Subcutaneous Octreotide as a Predictor of the Response to Treatment With Octreotide LAR ® .Somatostatin analogues are frequently used to treat acromegaly. To determine the value of the acute test (AT) with subcutaneous (SC) octreotide as a predictor of the response to treatment with octreotide LAR ® , we analyzed data from 20 patients. For the AT, blood was drawn before and two hours after the SC administration of octreotide for measuring GH. GH levels before and after the AT were 21.9ng/mL (2.3-143.4) and 3.1ng/mL (0.3-61.3), respectively. Control of the disease was defined as: GH< 2.5ng/mL and normal IGF-I anytime during treatment. Sensitivity, specificity, positive and negative predictive values of the AT were 0.9, 0.6, 0.69 and 0.86 for a reduction of 75% of the GH on the test. From our sample we conclude that a 75% reduction of the GH levels during the acute test was able to discriminate patients with a higher or lower chance of responding to treatment.

show abstract

“…Estas últimas têm sido relatadas em até 50% dos pacientes, mas freqüen-temente duram apenas l a 2 dias e podem não recidivar após as injeções subseqüentes (119,128). Em 101 pacientes tratados por até 30 meses, surgiram cálculos biliares em quatro pacientes e microlitíase em outros quatro (134).…”

Section: Octreotidaunclassified

Tratamento medicamentoso dos tumores hipofisários. Parte I: prolactinomas e adenomas secretores de GH

Vilar

Naves

Freitas

et al. 2000

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO recente desenvolvimento de novas drogas, particularmente os aná-logos da somatotastina (SRIFa), representou um grande progresso na terapia dos tumores hipofisários. Os SRIFa mostram-se bastante eficazes na normalização dos níveis de GH e IGF-1 em acromegálicos e podem ser uma alternativa para a cirurgia transesfenoidal, mas seu uso como terapia primária da acromegalia fica limitado pelo pequeno efeito dessas drogas na redução das dimensões do tumor. Os resultados preliminares com os antagonistas do receptor de GH, como o pegvisomant, são bastante animadores. Tais drogas permitem a normalização do IGF-1 e melhora clínica em mais de 80% dos casos; entretanto, não causam redução tumoral. Agonistas dopaminérgicos (DA) representam a terapia de escolha para microprolactinomas sintomáticos e macroprolactinomas, permitindo normalização dos níveis da prolactina e redução do volume do adenoma na maioria dos pacientes. Podem também ser eventualmente eficazes em acromegálicos, sobretudo naqueles com adenomas co-secretores de prolactina e níveis não muito elevados de GH e IGF-1. Devido a sua maior eficácia e melhor tolerabilidade, a cabergolina representa o DA de escolha para o manuseio dos prolactinomas e da acromegalia. ABSTRACTThe recent development of new drugs, particularly the somatostatin analogues (SRIFa), represents a great advance in the therapy of pituitary tumours. SRIFas are very effective in normalizing GH and IGF-1 levels in acromegaly and may be an effective alternative to transsphenoidal surgery. However, their usefulness as primary therapy for acromegaly is limited due to the small effect on tumour size. According to early data from clinical trials, pegvisomant, a GH receptor antagonist, seems to be a promising therapeutic tool in the management of acromegalic patients. This drug induces significant clinical improvement and normalization of IGF-1 levels in nearly all patients. However, it does not induce tumor shrinkage. Dopamine agonists (DA) are the preferred therapy for both symptomatic microprolactinomas and macroprolactinomas; their use result in normalization of prolactin levels and tumor shrinkage in most treated patients. They also may be useful in acromegaly, mainly in patients whose adenoma co-secrete prolactin and those with mild elevation of GH and IGF-1 levels. Due to its greater effectiveness and better tolerability, cabergoline represents the DA of choice for the management of prolactinomas and acromegaly.

show abstract

Somatostatin receptor imaging in somatotroph and non‐functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide

Cited by 56 publications

References 26 publications

Somatostatin Analogs as Radiodiagnostic Tools

Somatostatin Analogs as Radiodiagnostic Tools

Teste agudo com octreotide subcutâneo como preditor de resposta ao tratamento com octreotide LAR®

Tratamento medicamentoso dos tumores hipofisários. Parte I: prolactinomas e adenomas secretores de GH

Contact Info

Product

Resources

About